A prolactinoma is a noncancerous (benign) pituitary tumor that produces a hormone called prolactin. This results in too much prolactin in the blood.
Adenoma - secreting; Prolactin - secreting adenoma of the pituitary
Prolactin is a hormone that triggers the breasts to produce milk (lactation).
Prolactinoma is the most common type of pituitary tumor (adenoma) that produces a hormone. It makes up at least 30% of all pituitary adenomas. Almost all pituitary tumors are noncancerous (benign). Prolactinoma may occur as part of an inherited condition called multiple endocrine neoplasia type 1 (MEN 1)
Prolactinomas occur most commonly in people under age 40. They are more common in women than in men, but are rare in children.
At least half of all prolactinomas are very small (less than 1 centimeter or 3/8 of an inch in diameter). These small tumors occur more often in women.
Larger tumors are more common in men. They tend to occur at an older age. The tumor can grow to a large size before symptoms appear.
The tumor is often detected at an earlier stage in women than in men because of irregular menstrual periods.
Abnormal milk flow from the breast in a woman who is not pregnant or nursing (galactorrhea)
Decreased sexual interest
Decreased peripheral vision
- Stopping of menstruation not related to menopause, or irregular menstruation
- Vision changes
Symptoms caused by pressure from a larger tumor may include:
- Nasal drainage
- Nausea and vomiting
- Problems with the sense of smell
- Vision changes, such as double vision, drooping eyelids or visual field loss
There may be no symptoms, especially in men.
Exams and Tests
The health care provider will perform a physical exam and ask about your symptoms. You will also be asked about medicines and substances you are taking.
Tests that may be ordered include:
- Pituitary MRI or brain CT scan
- Testosterone level in men
- Prolactin level
- Thyroid function tests
Medicine is usually successful in treating prolactinoma. Some people have to take these medicines for life. Other people can stop taking the medicines after a few years, especially if their tumor was small when it was discovered or has disappeared from the MRI. But there is a risk that the tumor may grow and produce prolactin again, especially if it was a large tumor.
A large prolactinoma can sometimes get larger during pregnancy.
Surgery is done in some cases when symptoms are severe, such as a sudden worsening of vision.
Radiation is usually only used in people with prolactinoma that continues to grow or gets worse after both medicine and surgery have been tried. Radiation may be given in the form of:
- Conventional radiation
- Gamma knife (stereotactic radiosurgery): a type of radiation therapy that focuses high-powered x-rays on a small area in the brain.
The outlook is usually excellent, but depends on the success of medical treatment or surgery. Getting tested to check whether the tumor has returned after treatment is important.
Treatment for prolactinoma may change the levels of other hormones in the body, especially if surgery or radiation is performed.
High levels of estrogen or testosterone may be involved in the growth of a prolactinoma. Women with prolactinomas should be followed closely during pregnancy. They should discuss this tumor with their provider before taking birth control pills with a higher than usual estrogen content.
When to Contact a Medical Professional
See your provider if you have any symptoms of prolactinoma.
If you have had a prolactinoma in the past, call your provider for a general follow-up, or if your symptoms return.
Bronstein MD. Disorders of prolactin secretion and prolactinomas. In: Jameson JL, De Groot LJ, de Kretser DM, et al, eds. Endocrinology: Adult and Pediatric. 7th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 7.
Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. part 1: Clinical manifestations and diagnostic challenges. J Clin Neurosci. 2015;22(10):1562-1567. PMID: 26256063 www.ncbi.nlm.nih.gov/pubmed/26256063.
Wong A, Eloy JA, Couldwell WT, Liu JK. Update on prolactinomas. part 2: Treatment and management strategies. J Clin Neurosci. 2015;22(10):1568-1574. PMID: 26243714 www.ncbi.nlm.nih.gov/pubmed/26243714.
- Last reviewed on 5/7/2017
- Brent Wisse, MD, Associate Professor of Medicine, Division of Metabolism, Endocrinology & Nutrition, University of Washington School of Medicine, Seattle, WA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is the first of its kind, requiring compliance with 53 standards of quality and accountability, verified by independent audit. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial process. A.D.A.M. is also a founding member of Hi-Ethics (www.hiethics.com) and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 2002 A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.